Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Barton

Showing results (121-130 of 296) with videos related to

Pageof 30
Sort By:
Annals of the Rheumatic Diseases|June 2, 2016
High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohortMeghna Jani, John D Isaacs, Ann W Morgan, et al.
Arthritis and Rheumatism|November 10, 2010
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven lociDarren Plant, John Bowes, Catherine Potter, et al.
Rheumatology (Oxford, England)|January 19, 2017
The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohortSamantha Louise Smith, Darren Plant, Stephen Eyre, et al.
Rheumatology (Oxford, England)|August 28, 2016
Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levelsMeghna Jani, John D Isaacs, Ann W Morgan, et al.
Annals of the Rheumatic Diseases|December 11, 2013
Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approachAnnie Yarwood, Sebastien Viatte, Darren Plant, et al.
Lancet (London, England)|August 28, 2015
The skin microbiome in psoriatic arthritis: methodology development and pilot dataMadhura Castelino, Stephen Eyre, John Moat, et al.
Human Molecular Genetics|August 21, 2008
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritisJames R Maxwell, Catherine Potter, Kimme L Hyrich, et al.
The Lancet. Rheumatology|October 3, 2025
Synovial immunopathology in psoriatic arthritis: cellular and molecular insightsRyan Malcolm Hum, Maria Christofi, Samantha Louise Smith, et al.
Rheumatology (Oxford, England)|October 11, 2019
Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritisNisha Nair, Darren Plant, Suzanne M Verstappen, et al.
The Pharmacogenomics Journal|December 11, 2019
Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patientsStephanie F Ling, Nisha Nair, Suzanne M M Verstappen, et al.
Pageof 30

Showing results (121-130 of 296) with videos related to

Sort By:
Pageof 30
Annals of the Rheumatic Diseases|June 2, 2016
High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohortMeghna Jani, John D Isaacs, Ann W Morgan, et al.
Arthritis and Rheumatism|November 10, 2010
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven lociDarren Plant, John Bowes, Catherine Potter, et al.
Rheumatology (Oxford, England)|January 19, 2017
The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohortSamantha Louise Smith, Darren Plant, Stephen Eyre, et al.
Rheumatology (Oxford, England)|August 28, 2016
Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levelsMeghna Jani, John D Isaacs, Ann W Morgan, et al.
Annals of the Rheumatic Diseases|December 11, 2013
Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approachAnnie Yarwood, Sebastien Viatte, Darren Plant, et al.
Lancet (London, England)|August 28, 2015
The skin microbiome in psoriatic arthritis: methodology development and pilot dataMadhura Castelino, Stephen Eyre, John Moat, et al.
Human Molecular Genetics|August 21, 2008
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritisJames R Maxwell, Catherine Potter, Kimme L Hyrich, et al.
The Lancet. Rheumatology|October 3, 2025
Synovial immunopathology in psoriatic arthritis: cellular and molecular insightsRyan Malcolm Hum, Maria Christofi, Samantha Louise Smith, et al.
Rheumatology (Oxford, England)|October 11, 2019
Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritisNisha Nair, Darren Plant, Suzanne M Verstappen, et al.
The Pharmacogenomics Journal|December 11, 2019
Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patientsStephanie F Ling, Nisha Nair, Suzanne M M Verstappen, et al.
Pageof 30